The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.
 
Masahiro Takada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kiowa Kirin; Lilly; Nippon Kayaku; Pfizer; Takeda
Research Funding - AstraZeneca; Daiichi Sankyo; Eisai; Nippon Kayaku
 
Shigeru Imoto
Speakers' Bureau - AstraZeneca; Novartis
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Kiowa Kirin; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
 
Takanori Ishida
Speakers' Bureau - Chugai Pharma; Eisai; Pfizer
Research Funding - Chugai Pharma; Eisai; Kiowa Kirin; Taiho Pharmaceutical
 
Yoshinori Ito
Research Funding - A2 Healthcare; AstraZeneca; Chugai Pharma; Covance; Daiichi Sankyo; Eisai; EPS Associates Co., Ltd.; IQVIA; Kiowa Kirin; Lilly; MSD; Novartis; PAREXEL; Taiho Pharmaceutical
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Hirofumi Mukai
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo; Eisai; Japan Agency for Medical Research and Development; Nippon Kayaku; Pfizer
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Eisai; Lilly; Novartis; Taiho Pharmaceutical; Takeda
 
Takafumi Ikeda
No Relationships to Disclose
 
Hironori Haga
No Relationships to Disclose
 
Toshiaki Saeki
Consulting or Advisory Role - Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Fuji Pharma; Kiowa Kirin; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Fuji Pharma; Hamamatsu Photonics; Kiowa Kirin; MSD; Nihon Medi-Physics; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sawai Pharmaceutical Co; Taiho Pharmaceutical
 
Kenjiro Aogi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Mochida Pharmaceutical Co. Ltd.; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Eisai; Takeda
 
Tomoharu Sugie
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Genomic Health; Kiowa Kirin; Lilly; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Eisai; Kiowa Kirin; Pfizer
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - Eisai
 
Shinji Ohno
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Eisai; Taiho Pharmaceutical
 
Hiroshi Ishiguro
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Chizuko Kanbayashi
No Relationships to Disclose
 
Takeshi Miyamoto
No Relationships to Disclose
 
Yasuo Ohashi
Leadership - EP-Cruse Co., Ltd; EP-Techno; Statcom
Stock and Other Ownership Interests - Statcom
Honoraria - Chugai Pharma; Daiichi Sankyo; Kowa; Sanofi; Shionogi
Research Funding - Medical Members System (Inst)
 
Masakazu Toi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genomic Health; Konica Minolta; Kyowa Hakko Kirin; Lilly; Novartis; Pfizer; Shimadzu; Taiho Pharmaceutical; TAKEDA; Yakult Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Konica Minolta; Kyowa Hakko Kirin
Speakers' Bureau - AstraZeneca; Lilly; Pfizer
Research Funding - AFI technology; Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Japan Breast Cancer Research Group; Kyoto Breast cancer Research Network; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Shimadzu; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - JP 2017-143763 WO2017/131162A1 (Inst); PCT/JP2016/004374 (Inst)
Travel, Accommodations, Expenses - Eisai; Takeda
Other Relationship - Japan Breast Cancer Research Group; Japan Breast Cancer Research Group; Kyoto Breast Cancer Research Network; Organization for Oncology and Translational Research